1-10 of 10
Danny Rischin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT034: Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGFβ inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (CSCC)

Free
John M. Kaczmar, Eric Sherman, Gino K. In, Glenn J. Hanna, Christine H. Chung, Tamara A. Sussman, Neal S. Akhave, Fiona Day, Danny Rischin, Allen Lau, Rachel L. Salazar, Deborah J. Wong
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT034.
https://doi.org/10.1158/1538-7445.AM2025-CT034
Published: 25 April 2025
View article titled, Abstract CT034: Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGFβ inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (CSCC)
Journal Articles

Abstract 5094: Immunotherapy in advanced cutaneous non-melanomatous spindle cell neoplasms

Free
Luke S. McLean, Annette M. Lim, Christopher Angel, Richard J. Young, Angela Pizzolla, Stuart Archer, Alesha A. Thai, Benjamin Solomon, Jeremy Lewin, Danny Rischin
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5094.
https://doi.org/10.1158/1538-7445.AM2024-5094
Published: 22 March 2024
View article titled, Abstract 5094: Immunotherapy in advanced cutaneous non-melanomatous spindle cell neoplasms
Journal Articles

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Free
Barbara Burtness, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Joy Ge, Ramona Swaby, Burak Gumuscu, Kevin Harrington
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): LB-258.
https://doi.org/10.1158/1538-7445.AM2020-LB-258
Published: 15 August 2020
View article titled, Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score &lt;1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
Journal Articles

Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma

Free
Lillian L. Siu, Lisa Licitra, Yun Gan Tao, Chia-Jui Yen, Danny Rischin, John Waldron, Barbara Burtness, Vincent Gregoire, Sanjiv Agarwala, Jeffrey Yorio, Jean-Pierre DeLord, Sercan Aksoy, Sadakatsu Ikeda, Ruey-Long Hong, Joy Yang Ge, Holly Brown, Behzad Bidadi, Jean-Pascal Machiels
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT163.
https://doi.org/10.1158/1538-7445.AM2018-CT163
Published: 01 July 2018
View article titled, Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma
Journal Articles

Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Free
Eric Angevin, Todd M. Bauer, Catherine E. Ellis, Hui Gan, Rigel Hall, Aaron Hansen, Axel Hoos, Roxanne C. Jewell, Jessica Katz, Juan Martin-Liberal, Michele Maio, Patrick A. Mayes, Jolly Mazumdar, Michael Millward, Danny Rischin, Jan H. Schellens, Sapna Yadavilli, Helen Zhou
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT039.
https://doi.org/10.1158/1538-7445.AM2017-CT039
Published: 01 July 2017
View article titled, Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors
Journal Articles

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

Free
Francis W. Hunter, Richard J. Young, Zvi Shalev, Ravi N. Vellanki, Jingli Wang, Yongchuan Gu, Naveen Joshi, Sreevalsan Sreebhavan, Ilan Weinreb, David P. Goldstein, Jason Moffat, Troy Ketela, Kevin R. Brown, Marianne Koritzinsky, Benjamin Solomon, Danny Rischin, William R. Wilson, Bradly G. Wouters
Journal: Cancer Research
Cancer Res (2015) 75 (19): 4211–4223.
https://doi.org/10.1158/0008-5472.CAN-15-1107
Published: 30 September 2015
View article titled, Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
Open the PDF for Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs in another window
Includes: Supplementary data
Journal Articles

Abstract 4693: Characterization of the differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas and correlation with patient outcome.

Free
Annette M. Lim, Hongdo Do, Richard J. Young, Stephen Q. Wong, Christopher Angel, Marnie Collins, Elena Takano, June Corry, Stephen B. Fox, David Wiesenfeld, Stephen Kleid, Elizabeth Sigston, Bernard Lyon, Danny Rischin, Alexander Dobrovic, Benjamin Solomon
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4693.
https://doi.org/10.1158/1538-7445.AM2013-4693
Published: 15 April 2013
View article titled, Abstract 4693: Characterization of the differential mechanisms of CDKN2A inactivation in oral tongue squamous cell carcinomas and correlation with patient outcome.
Journal Articles

A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck

Free
J. Simon Stewart, Ezra Cohen, Lisa Licitra, Carla Van Herpen, Chonlakiet Khorprasert, Denis Soulieres, Pavel Vodvarka, Danny Rischin, Avgust Garin, Serban Ghiorghiu, Laura Hargreaves, Alison Armour, Everett Vokes
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3522.
Published: 01 May 2007
View article titled, A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck
Journal Articles

An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin

Free
Richard W. Tothill, Adam Kowalczyk, Danny Rischin, Alex Bousioutas, Izhak Haviv, Ryan K. van Laar, Paul M. Waring, John Zalcberg, Robyn Ward, Andrew V. Biankin, Robert L. Sutherland, Susan M. Henshall, Kwun Fong, Jonathan R. Pollack, David D.L. Bowtell, Andrew J. Holloway
Journal: Cancer Research
Cancer Res (2005) 65 (10): 4031–4040.
https://doi.org/10.1158/0008-5472.CAN-04-3617
Published: 16 May 2005
View article titled, An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin
Open the PDF for An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin in another window
Includes: Supplementary data
Journal Articles

Development of an expression-based site of origin diagnostic designed for clinical application to cancer of unknown primary

Free
Richard W. Tothill, Adam Kowalczyk, Alex Boussioutas, Izhak Haviv, Paul Waring, Danny Rischin, Andrew J. Holloway, David D. L. Bowtell
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 383.
Published: 01 May 2005
View article titled, Development of an expression-based site of origin diagnostic designed for clinical application to cancer of unknown primary